GLX Analytix is a startup based in the United States.
GLX Analytix develops a clinical-stage blood test platform that measures glycocalyx sugar structures in blood to diagnose and monitor neuropsychiatric, neurodegenerative, and autoimmune brain diseases using AI-driven biomarker signatures.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.